Compare ADMA Biologics Inc (ADMA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Zimmer Biomet Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Zimmer Biomet Holdings Inc trades at $88.28 (market cap $17.30B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 8.1× ADMA Biologics Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ZBH | |
|---|---|---|
Market Cap | $2.13B | $17.30B |
Sector | Health | Health |
52-Week High | $20.38 | $107.71 |
52-Week Low | $7.60 | $79.58 |
Enterprise Value | $2.20B | $24.34B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Zimmer Biomet (ZBH) trades at $89.41, up 2.22% with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with 70% gross margins and revenue growth to $8.23B in 2025, though net margins compressed to 8.56%. Recent developments include a $140M acquisition and plans to hire 500 tech employees in India, supporting growth initiatives. Valuation metrics appear reasonable with P/E of 23.25 and P/S of 2.11.
ZBH offers moderate upside to the $98.33 consensus target with analyst sentiment mixed (43% buy, 50% hold). Key risks include rising debt levels (debt-to-asset ratio increased to 32.57% in 2025) and margin pressure. The company's $1B share repurchase program and dividend provide shareholder returns, but execution on growth initiatives remains critical for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
